Breaking News Headlines Today

News about Johnson & Johnson

Stay current with all the latest and breaking news about Johnson & Johnson, compare headlines and perspectives between news sources on stories happening today. In total, 75 stories have been published about Johnson & Johnson which Ground News has aggregated in the past 3 months.

Covered Most By

Local News Publishers

Suggest a source

Looking for a source we don't already have? Suggest one here.

Top Johnson & Johnson News

Johnson & Johnson · Ohio

U.S. FDA Approval of INLEXZO™ (Gemcitabine Intravesical System) Set to Transform How Certain Bladder Cancers Are Treated

57% Center coverage: 14 sources

First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for reinduction1 See the Story

Johnson & Johnson

Osimertinib Plus Chemotherapy Offers Overall Survival Advantage for Patients with EGFR-Mutated Advanced NSCLC

100% Center coverage: 4 sources

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).See the Story

Johnson & Johnson · United States

US FDA approves J&J's bladder cancer treatment

100% Center coverage: 1 sources

(Reuters) -The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a potential alternative to surgically remove the organ.See the Story

From Clinic to Global Strategy: Dr. Caroline Blackie Named VP of Medical Affairs for Vision at J&J

Dr. Caroline Blackie. All photos provided by Dr. Blackie. Caroline Blackie, PhD, OD, MS, has long believed that “the grass is greener where you water it.” Today, as the newly appointed vice president of medical affairs for vision at Johnson & Johnson, she channels that philosophy into a global strategy for evidence-based eye care. With an impressive academic background spanning optometry, statistics, neurobiology and health informatics—and a car…Johnson & Johnson · New Brunswick Read Article

US FDA approves J&J's bladder cancer treatment

100% Center coverage: 1 sources

U.S. FDA Approval of INLEXZO™ (Gemcitabine Intravesical System) Set to Transform How Certain Bladder Cancers Are Treated

57% Center coverage: 14 sources

Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage

Lilly’s BTK Jaypirca will continue to compete with AbbVie and J&J’s Imbruvica and BeOne Medicines’s Brukinsa.Johnson & Johnson See the Story

Ronovo Surgical raises $67M, led by J&J venture arm

100% Center coverage: 1 sources

Ronovo, a Chinese surgical robotics company, will also team with a J&J subsidiary in Shanghai to sell Ronovo’s soft tissue platform and complementary J&J technologies.Johnson & Johnson · Shanghai Read Article

Osimertinib Plus Chemotherapy Offers Overall Survival Advantage for Patients with EGFR-Mutated Advanced NSCLC

100% Center coverage: 4 sources

87% Lower Cancer Drug Resistance: J&J's RYBREVANT-LAZCLUZE Combo Extends Lung Cancer Survival to 4+ Years

100% Center coverage: 3 sources

RYBREVANT plus LAZCLUZE reduces MET amplification to 3% vs 13% with osimertinib in EGFR-mutated NSCLC. Phase 3 MARIPOSA study projects survival beyond 4 years, marking 1-year improvement.Johnson & Johnson See the Story

Ronovo Surgical Closes Series D Financing

Open the article to view the coverage from The AI JournalJohnson & Johnson · Shanghai See the Story

600 Extra Days of Life: Johnson & Johnson's Heart Pump Shows Breakthrough Results in 10-Year Study

70% Center coverage: 20 sources

DanGer Shock trial data shows J&J's Impella CP reduces mortality by 16.3% over 10 years in heart attack patients with cardiogenic shock. Study of 360 patients published in NEJM.Johnson & Johnson · Madrid See the Story

Notable healthcare headlines for the week: UnitedHealth, J&J and Eli Lilly in focus (XLV:NYSEARCA)

100% Right coverage: 1 sources

Explore the latest healthcare market shifts: gains, losses, policy impacts, and major acquisitions, including Eli Lilly's obesity drug progress.Johnson & Johnson · United States Read Article

News about Johnson & Johnson

News about Johnson & Johnson

Covered Most By

Local News Publishers

Top Johnson & Johnson News

U.S. FDA Approval of INLEXZO™ (Gemcitabine Intravesical System) Set to Transform How Certain Bladder Cancers Are Treated

Osimertinib Plus Chemotherapy Offers Overall Survival Advantage for Patients with EGFR-Mutated Advanced NSCLC

US FDA approves J&J's bladder cancer treatment

From Clinic to Global Strategy: Dr. Caroline Blackie Named VP of Medical Affairs for Vision at J&J

US FDA approves J&J's bladder cancer treatment

U.S. FDA Approval of INLEXZO™ (Gemcitabine Intravesical System) Set to Transform How Certain Bladder Cancers Are Treated

Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage

Ronovo Surgical raises $67M, led by J&J venture arm

Osimertinib Plus Chemotherapy Offers Overall Survival Advantage for Patients with EGFR-Mutated Advanced NSCLC

87% Lower Cancer Drug Resistance: J&J's RYBREVANT-LAZCLUZE Combo Extends Lung Cancer Survival to 4+ Years

Ronovo Surgical Closes Series D Financing

600 Extra Days of Life: Johnson & Johnson's Heart Pump Shows Breakthrough Results in 10-Year Study

Notable healthcare headlines for the week: UnitedHealth, J&J and Eli Lilly in focus (XLV:NYSEARCA)

Covered Most By

Media Bias Breakdown

Breaking News Topics Related to Johnson & Johnson

From Clinic to Global Strategy: Dr. Caroline Blackie Named VP of Medical Affairs for Vision at J&J

US FDA approves J&J's bladder cancer treatment

U.S. FDA Approval of INLEXZO™ (Gemcitabine Intravesical System) Set to Transform How Certain Bladder Cancers Are Treated

Lilly to seek Jaypirca label expansion for first-line CLL/SLL usage

Ronovo Surgical raises $67M, led by J&J venture arm

Osimertinib Plus Chemotherapy Offers Overall Survival Advantage for Patients with EGFR-Mutated Advanced NSCLC

87% Lower Cancer Drug Resistance: J&J's RYBREVANT-LAZCLUZE Combo Extends Lung Cancer Survival to 4+ Years

Ronovo Surgical Closes Series D Financing

600 Extra Days of Life: Johnson & Johnson's Heart Pump Shows Breakthrough Results in 10-Year Study

Notable healthcare headlines for the week: UnitedHealth, J&J and Eli Lilly in focus (XLV:NYSEARCA)